Cancer Research UK Manchester Institute

Back to Research Groups

Caroline Dive

After completing my PhD studies in Cambridge, Caroline moved to Aston University's School of Pharmaceutical Sciences in Birmingham where she started her own group studying mechanisms of drug induced tumour cell death. She then moved to what became the Faculty of Life Sciences at The University of Manchester to continue this research. Caroline was awarded a Lister Institute of Preventative Medicine Research Fellowship before moving to the CRUK Manchester Institute in 2003.  Here she set up the Clinical and Experimental Pharmacology Group interfacing with the Derek Crowther Unit for early clinical trials at The Christie. Caroline is currently a Senior Group Leader at the CRUK Manchester Institute and Professor of Pharmacology at The University of Manchester.


Deputy Group Leader

Ged Brady

Phase I Lead

Malcolm Ranson


Lung Cancer Lead

Fiona Blackhall


Biostatistics Lead

Andrew Renehan


Senior Staff Scientists

Jonathan Tugwood

Stephen Walker


Staff Scientists

Jeff Cummings

Dominic Rothwell


Clinical Lecturers

Emma Dean

Alastair Greystoke

Matthew Krebs

Cliona Kirwan

Associate Scientists

Kathryn Simpson

Chris Morrow

Service Manager

David Moore


Postdoctoral Fellows

Mahmood Ayub

Alison Backen

Ivona Baricevic-Jones

Becky Bola

Jian Mei Hou

Radoslaw Polanski

Cong Zhou


Clinical Fellows

Kyaw Aung

Louise Carter

Leila Khoja

Kalena Marti Marti

Robert Metcalf

Danielle Shaw

Laura Cove Smith

Graduate Students

Danielle Potter

Shaun Villa


Scientific Officers
Jenny Antonello

Stephen Bramley

Jessica Booth

Damien Brown

Debbie Burt

Fouziah Butt

John Castle

Samson Chinien

Jakub Chudziak

Martin Dawson

Olive Denneny

Shital Dulabh

Suzanne Faulkner

Joseph Halstead

Grace Hampson

Cassandra Hodgkinson

Paul Kelly

Matthew Lancashire

Daniel Morris

Karen Morris

Andrew Price

Jackie Pierce

Lynsey Priest

Tony Price

Robert Sloane

Nigel Smith


Laboratory Manager

Martin Greaves

Scientific Assistant

Aileen Jardine


Administration Assistants

Judith Thorpe

Lisa Waters 

Clinical and Experimental Pharmacology Group (CEP)

The Remit and Organisation of the Clinical and Experimental Pharmacology Group

The goals of CEP are therefore (i) To spearhead early clinical evaluation of novel Mechanism Based Therapies by providing pharmacokinetic and innovative pharmacodynamic biomarker analyses to GCLP standards using state of the art technologies, and (ii) To respond to a national deficit in clinical and non-clinical translational pharmacology specialists by providing world class training for biomarker research in oncology. CEP was expanded significantly between 2004-2007 reflecting the breadth of its activities (in vitro, preclinical in vivo and clinical). A QA system was developed and implemented to meet the requirements of Good Clinical Laboratory Practice (GCLP) applied to clinical sample analyses where data have the potential to influence patient management. 2006 saw CEP move into purpose built, state of the art, translational laboratories at CRUK Manchester Institute.

Twin research themes within CEP are the evaluation of MBTs that promote tumour apoptosis (exploiting expertise of Professors Dive & Ranson) and those that prevent tumour angiogenesis (combining expertise in CEP with that of the adjacent collaborator Prof Gordon Jayson). The three Disease Focus Subgroups within CEP are lung cancer (led by Dr Fiona Blackhall), Colorectal Cancer (led by Mr Renehan) and Paediatric Cancers (led by Dr Guy Makin). CEP also extended its collaborations on biomarkers this year with clinical colleagues within MCRC (Prof Noel Clarke, GU cancers and Professors T Illidge and Radford, Haematological Malignancies).

CEP staff are organised into several teams, PD biomarkers, QA, PK, Clinical Proteomics and Biomarker Discovery, In vivo Pharmacology, and Molecular Pharmacology. Translational research studies include investigations of efficacy of novel drugs in hypoxic tumour cells (collaborating with Prof Ian Stratford and Dr Kaye Williams, School of Pharmacy, MCRC), and on optimal combinations and scheduling of novel with conventional therapeutics. Pre-clinically, CEP also develops and tests in vivo models with ‘switchable’ expression of drug targets or pathways. These models will facilitate the discovery of serological biomarkers, the development of tumour imaging tools with colleagues at the Wolfson Molecular Imaging Centre and evaluate on and off target effects of novel MBTs.

Training the Next Generation of Early Clinical Trialists

Training of translational scientists and academic pharmacologists (a national deficit): is achieved through a Clinical Pharmacology Fellowship Scheme for promising young doctors initiated in 2006. The Scheme is equally funded by CRUK and AstraZeneca leads to award of a PhD in Clinical and Experimental Pharmacology and has 2 Fellows in post and 2 recruited to start in 2007. The Fellows’ Projects are all biomarkers based and involve collaborations with many clinical colleagues within the MCRC. Fellows undertake their laboratory based research in CEP and elsewhere within MCRC and at AZ and attend one clinic per week in DCU.